CanSino Biologics Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
2,291
- Stock Symbol
-
06185
- Investments
-
2
- Share Price
-
$2.98
- (As of Friday Closing)
CanSino Biologics General Information
Description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
Contact Information
- 401-420, 4th Floor, Biomedical Park
- 185 South Avenue, TEDA West District
- Tianjin
- China
CanSino Biologics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.98 | $2.97 | $2.62 - $12.29 | $1.62B | 247M | 1.43M | -$0.82 |
CanSino Biologics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 1,376,055 | 2,898,675 | 7,560,903 | 9,526,569 |
| Revenue | 70,783 | 153,097 | 665,890 | 2,684 |
| EBITDA | (287,794) | (145,314) | 306,171 | (57,409) |
| Net Income | (201,322) | (135,040) | 296,479 | (57,412) |
| Total Assets | 1,317,212 | 1,662,337 | 1,862,881 | 1,032,874 |
| Total Debt | 270,802 | 391,435 | 215,688 | 21,817 |
CanSino Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CanSino Biologics Comparisons
Industry
Financing
Details
000000
000000
CanSino Biologics Competitors (36)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sinovac | Corporation | Beijing, China | 0000 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000 | 000000&0 | |
| 00 000000000 | Corporation | Brisbane, CA | 0 | 000.00 | 000000000 | 000.00 |
| 000000000 | Venture Capital-Backed | Paris, France | 00 | 00.000 | 000000 0 |
CanSino Biologics Patents
CanSino Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2023549995-A | Atomization cup and its use in atomization inhalation administration | Pending | 29-Nov-2021 | ||
| JP-3244837-U | Atomization cup and its use in atomization inhalation administration | Active | 29-Nov-2021 | ||
| CA-3182438-A1 | Method for preparing adenovirus vector vaccine by means of perfusion culture process | Pending | 09-Nov-2020 | 000000000 | |
| EP-4151725-A1 | Method for preparing adenovirus vector vaccine by means of perfusion culture process | Pending | 09-Nov-2020 | 000000000 | |
| US-20230313225-A1 | Method for preparing adenovirus vector vaccine by means of perfusion culture process | Pending | 09-Nov-2020 | C12N15/86 |
CanSino Biologics Executive Team (9)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Xuefeng Yu Ph.D | Co-Founder, Chief Executive Officer & Chairman | ||
| Shou Chao Ph.D | Chief Operating Officer & Executive Director of the Board | ||
| Tao Zhu Ph.D | Co-Founder, Executive Director and Chief Scientific Officer | ||
| Helen Mao Ph.D | Founder, Executive Vice President & Controlling Shareholder | ||
| Jing Wang | Board Member & Executive |
CanSino Biologics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jing Wang | CanSino Biologics | Board Member & Executive | 000 0000 |
| Nisa Leung | Qiming Venture Partners | Board Member | 000 0000 |
| Shuifa Gui | CanSino Biologics | Board Member | 000 0000 |
| Xuefeng Yu Ph.D | CanSino Biologics | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
CanSino Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
CanSino Biologics Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biolink Pharmaceutical | 20-Feb-2023 | 00000 0000 | Medical Supplies | ||
| Thousand Oaks Biopharmaceuticals | 30-Sep-2020 | Secondary Transaction - Private | 0000 | Biotechnology |
CanSino Biologics ESG
Risk Overview
Risk Rating
Updated March, 06, 2023
35.35 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 418
Rank
Percentile
